UBS Group
DTIL icon

UBS Group’s Precision BioSciences DTIL Stock Holding History

UBS Group’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$446K Buy
81,133
+19,801
+32% +$91.3K ﹤0.01% 6159
2025
Q4 		$255K Buy
61,332
+36,856
+151% +$209K ﹤0.01% 6453
2025
Q3 		$135K Sell
24,476
-27,130
-53% -$130K ﹤0.01% 6919
2025
Q2 		$217K Sell
51,606
-5,421
-10% -$26.7K ﹤0.01% 6665
2025
Q1 		$272K Sell
57,027
-11,588
-17% -$59K ﹤0.01% 6325
2024
Q4 		$261K Buy
68,615
+66,732
+3,544% +$487K ﹤0.01% 6293
2024
Q3 		$16.9K Buy
1,883
+1,676
+810% +$16.1K ﹤0.01% 7466
2024
Q2 		$2.01K Buy
207
+1
+0.5% +$12 ﹤0.01% 8441
2024
Q1 		$2.79K Sell
206
-2,752
-93% -$33.7K ﹤0.01% 7827
2023
Q4 		$32.4K Buy
2,958
+300
+11% +$3.23K ﹤0.01% 6803
2023
Q3 		$27.2K Buy
2,658
+497
+23% +$7.64K ﹤0.01% 6641
2023
Q2 		$34.1K Buy
2,161
+2,056
+1,958% +$47K ﹤0.01% 6664
2023
Q1 		$2.37K Sell
105
-505
-83% -$16.6K ﹤0.01% 8524
2022
Q4 		$21.8K Buy
610
+486
+392% +$19.2K ﹤0.01% 7564
2022
Q3 		$5K Buy
124
+86
+226% +$4.09K ﹤0.01% 9185
2022
Q2 		$2K Hold
38
– – ﹤0.01% 9532
2022
Q1 		$4K Sell
38
-4,762
-99% -$647K ﹤0.01% 9285
2021
Q4 		$1.07M Buy
4,800
+1,920
+67% +$536K ﹤0.01% 4334
2021
Q3 		$997K Buy
2,880
+2,304
+400% +$781K ﹤0.01% 4200
2021
Q2 		$217K Sell
576
-10,430
-95% -$3.13M ﹤0.01% 5279
2021
Q1 		$3.42M Buy
11,006
+6,450
+142% +$2.26M ﹤0.01% 3000
2020
Q4 		$1.14M Sell
4,556
-2,180
-32% -$534K ﹤0.01% 3904
2020
Q3 		$1.25M Buy
6,736
+6,283
+1,387% +$1.25M ﹤0.01% 3480
2020
Q2 		$114K Sell
453
-97
-18% -$21.2K ﹤0.01% 5199
2020
Q1 		$100K Sell
550
-823
-60% -$215K ﹤0.01% 5291
2019
Q4 		$572K Buy
1,373
+1,236
+902% +$388K ﹤0.01% 4718
2019
Q3 		$34K Sell
137
-1,956
-93% -$637K ﹤0.01% 6413
2019
Q2 		$832K Buy
2,093
+1,783
+575% +$718K ﹤0.01% 3896
2019
Q1 		$167K Buy
+310
New +$165K ﹤0.01% 4728

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS Group's DTIL Position: Q1 2026 in Review

UBS Group increased its Precision BioSciences (DTIL) stake by 32% in Q1 2026, buying an estimated $91.3K and bringing the position to 81,133 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #6159.

UBS Group first reported a position in DTIL in Q1 2019 and has held it in 29 quarters since. The position peaked at $3.42M in Q1 2021. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • UBS Group held 81,133 shares of Precision BioSciences worth $446K as of Q1 2026.
  • UBS Group bought 19,801 Precision BioSciences shares in Q1 2026, an estimated $91.3K.
  • Precision BioSciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6159 holding.
  • UBS Group first reported a position in Precision BioSciences in Q1 2019 and has held it in 29 quarters since.
  • UBS Group's Precision BioSciences position peaked at $3.42M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.